A study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of BR-6819 in male healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2017
At a glance
- Drugs BR 6819 (Primary) ; Tolvaptan
- Indications Heart failure
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- 28 Nov 2017 New trial record
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
- 29 Sep 2016 Results (n=14) assessing effect of BR-6819 1 mg on serum creatinine published in the Journal of Clinical Medicine Research.